|
According to National Comprehensive Cancer Network guidelines limited data supports that a 21-gene assay (oncotypeDx)may provide both prognostic information and prediction of benefit, or lack therof, from chemo in node negative, hormone receptor-positive bc treated with tamoxifen. ---- this statement footnotes a flow chart for systemic adjuvant treatment-hormone responsive disease-HER-2/NEU overexpressed bc. My path along this flowchart (tumor 0.6-1.0 cm, moderately/poorly diffreentiated or unfavorable features) ends with"adjuvant hormonal therapy; WITH OR WITHOUT chemo. This is why I wonder and again hope that my score of 17 -the highest number still called "low risk" supports my decision to get herceptin without chemo... and wonder has anyone else used oncotype to help decide.
|
Threaded Mode